Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download

Quantum Cyber secures exclusive drone tech license amid $55B US drone warfare budget boost

Market News
13 May 2026
Na
View Source
Bullish
pluang ai news

Quantum Cyber has secured an exclusive license for BP United's autonomous drone technology, including a sky defense platform capable of over 25 km range and fully autonomous operations. This move positions Quantum Cyber to capitalize on the Trump administration's proposed $55 billion budget for drone and autonomous warfare in 2027, a significant increase from the previous year. The company aims to build a comprehensive autonomous defense platform integrating various technologies, including quantum antenna systems. Further technology agreements and patent filings are expected as Quantum Cyber expands its defense capabilities.

More News

Silexion starts GMP manufacturing of SIL204 and gets Phase 2/3 trial approval for pancreatic cancer.

Silexion starts GMP manufacturing of SIL204 and gets Phase 2/3 trial approval for pancreatic cancer.

Silexion Therapeutics has begun Good Manufacturing Practice (GMP) clinical batch production of SIL204, a next-generation siRNA therapy targeting mutated KRAS in pancreatic cancer. The Helsinki Ethics Committee at Tel Aviv Sourasky Medical Center appr...

Company Fundamentals
Bullish
28 minutes ago
Brown-Forman rejects $15B cash bid from Sazerac weeks after ending talks with Pernod Ricard.

Brown-Forman rejects $15B cash bid from Sazerac weeks after ending talks with Pernod Ricard.

Brown-Forman, maker of Jack Daniel's, has declined a $15 billion all-cash acquisition offer from competitor Sazerac, which valued the company at $32 per share. This rejection follows the recent end of merger discussions between Brown-Forman and Perno...

Company Fundamentals
Bearish
1 hour ago
Andera Partners leads $20M Series D to advance Rivermark's FloStent for BPH treatment.

Andera Partners leads $20M Series D to advance Rivermark's FloStent for BPH treatment.

Andera Partners led a $20 million Series D funding round for Rivermark Medical, supporting the development and upcoming commercial launch of the FloStent System, a non-surgical, reversible device for treating benign prostatic hyperplasia (BPH). The f...

Company Fundamentals
Bullish
1 hour ago
SYX-5219 shows safety and immune benefits in Phase 1a trial for atopic dermatitis treatment

SYX-5219 shows safety and immune benefits in Phase 1a trial for atopic dermatitis treatment

Sitryx Therapeutics announced positive Phase 1a trial results for SYX-5219, an oral PKM2 modulator targeting atopic dermatitis. The trial in healthy volunteers showed the drug was safe, well tolerated, and demonstrated immune system modulation by red...

Company Fundamentals
Bullish
1 hour ago
Corbus Pharmaceuticals to present at RBC and Jefferies healthcare conferences in May and June 2026

Corbus Pharmaceuticals to present at RBC and Jefferies healthcare conferences in May and June 2026

Corbus Pharmaceuticals Holdings, a clinical-stage biotech company focused on oncology and obesity therapies, announced CEO Yuval Cohen will present corporate updates and meet investors at two major healthcare conferences in New York: the RBC Capital ...

Market News
Neutral
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App